Literature DB >> 19534676

2-Arylbenzimidazoles as antiviral and antiproliferative agents--Part 2.

Gabriella Vitale1, Paola Corona, Mario Loriga, Antonio Carta, Giuseppe Paglietti, Paolo La Colla, Bernardetta Busonera, Esther Marongiu, David Collu, Roberta Loddo.   

Abstract

In prosecution of an anti-Flaviviridae project a new series of variously substituted 2-diphenyl-benzimidazoles were synthesized and tested in vitro for antiviral and antiproliferative activities. Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae). The 5-Acetyl-2-(4'-nitrobiphenyl-4-yl)-1H-benzimidazole (24) emerged as potent active lead compound against Yellow Fever Virus (a Flavivirus) (EC(50) = 0.5 microM) and CVB-2 at 1 microM and was not cytotoxic, whereas the other title benzimidazoles showed no antiviral activity at concentrations not cytotoxic for the resting cell monolayers. Among the examined series, the most cytotoxic derivatives (11,12,14,16,18,19,20,21,23,25-30) against mock-infected MT-4 cells (CC50 < 8.0 microM) were evaluated against a panel of human cell lines derived from haematological and solid tumours,using 6-mercaptopurine (6-MP) and etoposide as reference drugs. In particular, compounds 26 and 28 showed a similar potency of 6-MP and etoposide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19534676     DOI: 10.2174/157340609790170542

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  1 in total

1.  Ethyl 2-(4-bromo-phen-yl)-1-sec-butyl-1H-benzimidazole-5-carboxyl-ate.

Authors:  Natarajan Arumugam; Nurziana Ngah; Shafida Abd Hamid; Aisyah Saad Abdul Rahim
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.